NVCHI
VIR icon

New Vernon Capital Holdings II’s Vir Biotechnology VIR Stock Holding History

New Vernon Capital Holdings II’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-9,702
Closed -$226K – 90
2023
Q1 		$226K Buy
9,702
+66
+0.7% +$1.69K 0.17% 45
2022
Q4 		$244K Buy
9,636
+1,556
+19% +$38.1K 0.2% 37
2022
Q3 		$156K Sell
8,080
-6,421
-44% -$163K 0.16% 42
2022
Q2 		$369K Buy
+14,501
New +$339K 0.3% 16

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

New Vernon Capital Holdings II's VIR Position: Q2 2023 in Review

New Vernon Capital Holdings II sold out of Vir Biotechnology (VIR) in Q2 2023, closing a stake of 9,702 shares — an estimated $226K sold.

New Vernon Capital Holdings II first reported a position in VIR in Q2 2022 and held it in 4 quarters. The position peaked at $369K in Q2 2022. 226 funds tracked by Wall St. Rank hold VIR as of Q2 2023.

  • New Vernon Capital Holdings II reported no remaining Vir Biotechnology position as of Q2 2023 after selling out during the quarter.
  • New Vernon Capital Holdings II sold 9,702 Vir Biotechnology shares in Q2 2023, an estimated $226K.
  • New Vernon Capital Holdings II first reported a position in Vir Biotechnology in Q2 2022 and held it in 4 quarters.
  • New Vernon Capital Holdings II's Vir Biotechnology position peaked at $369K in Q2 2022.
  • 226 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2023.

Based on New Vernon Capital Holdings II's 13F filing for Q2 2023, filed 14 Aug 2023.